Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 30 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 30 mg tablet (manufactured for First Horizon) following a single, oral 30 mg (1 × 30 mg tablet) dose administration in healthy adult subjects under fasting conditions.
Epistemonikos ID: f9c918399a6155197a7180b04a5ef63c59d8a370
First added on: May 05, 2024